These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29653132)

  • 41. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
    Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
    Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kinetics of hepatitis A virus replication in vivo and in vitro using negative-strand quantitative PCR.
    de Paula VS; Perse AS; Amado LA; de Morais LM; de Lima SM; Tourinho RS; Gaspar AM; Pinto MA
    Eur J Clin Microbiol Infect Dis; 2009 Oct; 28(10):1167-76. PubMed ID: 19468763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications.
    Alberti A; Piovesan S
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S174-8. PubMed ID: 25458777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo.
    de Freitas CS; Higa LM; Sacramento CQ; Ferreira AC; Reis PA; Delvecchio R; Monteiro FL; Barbosa-Lima G; James Westgarth H; Vieira YR; Mattos M; Rocha N; Hoelz LVB; Leme RPP; Bastos MM; Rodrigues GOL; Lopes CEM; Queiroz-Junior CM; Lima CX; Costa VV; Teixeira MM; Bozza FA; Bozza PT; Boechat N; Tanuri A; Souza TML
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007072. PubMed ID: 30699122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The FDA-approved drug sofosbuvir inhibits Zika virus infection.
    Bullard-Feibelman KM; Govero J; Zhu Z; Salazar V; Veselinovic M; Diamond MS; Geiss BJ
    Antiviral Res; 2017 Jan; 137():134-140. PubMed ID: 27902933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
    Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
    J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo.
    Leong CR; Funami K; Oshiumi H; Mengao D; Takaki H; Matsumoto M; Aly HH; Watashi K; Chayama K; Seya T
    Oncotarget; 2016 Oct; 7(42):68179-68193. PubMed ID: 27626689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Suppression of La antigen exerts potential antiviral effects against hepatitis A virus.
    Jiang X; Kanda T; Wu S; Nakamoto S; Saito K; Shirasawa H; Kiyohara T; Ishii K; Wakita T; Okamoto H; Yokosuka O
    PLoS One; 2014; 9(7):e101993. PubMed ID: 24999657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Performance of sofosbuvir and NITD008 in extrahepatic neuronal cells against HEV.
    Jagst M; Gömer A; Todt D; Steinmann E
    Antiviral Res; 2024 Jul; 227():105922. PubMed ID: 38825018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loxapine inhibits replication of hepatitis A virus in vitro and in vivo by targeting viral protein 2C.
    Matsuda M; Hirai-Yuki A; Kotani O; Kataoka M; Zheng X; Yamane D; Yokoyama M; Ishii K; Muramatsu M; Suzuki R
    PLoS Pathog; 2024 Mar; 20(3):e1012091. PubMed ID: 38478584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HAV replication in acute hepatitis with typical and atypical clinical course.
    Sagnelli E; Coppola N; Marrocco C; Onofrio M; Scarano F; Marotta A; Scolastico C; Catuogno A; Salzillo A; Sagnelli C; Piccinino F; Filippini P
    J Med Virol; 2003 Sep; 71(1):1-6. PubMed ID: 12858402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
    Ikeda M; Kawai Y; Mori K; Yano M; Abe K; Nishimura G; Dansako H; Ariumi Y; Wakita T; Yamamoto K; Kato N
    Liver Int; 2011 Jul; 31(6):871-80. PubMed ID: 21645219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of sofosbuvir for the treatment of hepatitis C virus infection.
    Lawitz E; Jacobson IM; Nelson DR; Zeuzem S; Sulkowski MS; Esteban R; Brainard D; McNally J; Symonds WT; McHutchison JG; Dieterich D; Gane E
    Ann N Y Acad Sci; 2015 Nov; 1358():56-67. PubMed ID: 26235748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.
    Castet V; Fournier C; Soulier A; Brillet R; Coste J; Larrey D; Dhumeaux D; Maurel P; Pawlotsky JM
    J Virol; 2002 Aug; 76(16):8189-99. PubMed ID: 12134024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication.
    Yu L; Aoki C; Shimizu Y; Shimizu K; Hou W; Yagyu F; Wen X; Oshima M; Iwamoto A; Gao B; Liu W; Gao GF; Kitamura Y
    J Virol Methods; 2010 Nov; 169(2):380-4. PubMed ID: 20713089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Hepatitis A virus infection. A review].
    Siegl G
    Praxis (Bern 1994); 2003 Oct; 92(40):1659-73. PubMed ID: 14579471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. T cells protect against hepatitis A virus infection and limit infection-induced liver injury.
    Misumi I; Mitchell JE; Lund MM; Cullen JM; Lemon SM; Whitmire JK
    J Hepatol; 2021 Dec; 75(6):1323-1334. PubMed ID: 34331968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.